Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression

Marco Bolis(SIB Swiss Institute of Bioinformatics), Daniela Bossi(Institute of Oncology Research), Arianna Vallerga(SIB Swiss Institute of Bioinformatics), Valentina Ceserani(Institute of Oncology Research), Manuela Cavalli(Institute of Oncology Research), Daniela Impellizzieri(Institute of Oncology Research), Laura Di Rito(Mario Negri Institute for Pharmacological Research), Eugenio Zoni(University of Bern), Simone Mosole(Institute of Oncology Research), Angela Rita Elia(Institute of Oncology Research), Andrea Rinaldi(Institute of Oncology Research), Ricardo Pereira Mestre(Institute of Oncology Research), Eugenia D’Antonio(Institute of Oncology Research), Matteo Ferrari(Ente Ospedaliero Cantonale), Flavio Stoffel(Ente Ospedaliero Cantonale), Fernando Jermini(Ente Ospedaliero Cantonale), Silke Gillessen(University of Applied Sciences and Arts of Southern Switzerland), Lukas Bubendorf(University Hospital of Basel), Peter Schraml(University Hospital of Zurich), Arianna Calcinotto(Institute of Oncology Research), Eva Corey(University of Washington), Holger Moch(University Hospital of Zurich), Martin Spahn(Lindenhofspital), George N. Thalmann(University of Bern), Marianna Kruithof‐de Julio(University of Bern), Mark A. Rubin(University of Bern), Jean‐Philippe Theurillat(Institute of Oncology Research)
Nature Communications
December 2, 2021
Cited by 109Open Access
Full Text

Abstract

Comprehensive genomic studies have delineated key driver mutations linked to disease progression for most cancers. However, corresponding transcriptional changes remain largely elusive because of the bias associated with cross-study analysis. Here, we overcome these hurdles and generate a comprehensive prostate cancer transcriptome atlas that describes the roadmap to tumor progression in a qualitative and quantitative manner. Most cancers follow a uniform trajectory characterized by upregulation of polycomb-repressive-complex-2, G2-M checkpoints, and M2 macrophage polarization. Using patient-derived xenograft models, we functionally validate our observations and add single-cell resolution. Thereby, we show that tumor progression occurs through transcriptional adaption rather than a selection of pre-existing cancer cell clusters. Moreover, we determine at the single-cell level how inhibition of EZH2 - the top upregulated gene along the trajectory - reverts tumor progression and macrophage polarization. Finally, a user-friendly web-resource is provided enabling the investigation of dynamic transcriptional perturbations linked to disease progression.


Related Papers

No related papers found

Powered by citation graph analysis